Who are Myrbetriq's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tolterodine , mirabegron, Solifenacin + Mirabegron, daytime dosing of mirabegron, nighttime dosing of mirabegron, Brovana, Mirabegron tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mirabegron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Myrbetriq — Competitive Intelligence Brief

Myrbetriq (MIRABEGRON) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta3-Adrenergic Agonist [EPC]. Area: Urology.

marketed beta3-Adrenergic Agonist [EPC] Beta-3 adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Myrbetriq (MIRABEGRON) — Apgdi. Myrbetriq works by activating the beta-3 adrenergic receptor in the bladder muscle, leading to relaxation and improved bladder control.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Myrbetriq TARGET	MIRABEGRON	Apgdi	marketed	beta3-Adrenergic Agonist [EPC]	Beta-3 adrenergic receptor	2012-01-01
tolterodine , mirabegron	tolterodine , mirabegron	Far Eastern Memorial Hospital	marketed	Antimuscarinic and beta-3 adrenergic agonist combination	Muscarinic M3 receptor and beta-3 adrenergic receptor
Solifenacin + Mirabegron	Solifenacin + Mirabegron	University of Aarhus	marketed	Antimuscarinic + Beta-3 adrenergic agonist combination	M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron)
daytime dosing of mirabegron	daytime dosing of mirabegron	Far Eastern Memorial Hospital	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
nighttime dosing of mirabegron	nighttime dosing of mirabegron	Far Eastern Memorial Hospital	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
Brovana	Brovana	Wake Forest University Health Sciences	marketed		Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-3 adrenergic receptor
Mirabegron tablet	Mirabegron tablet	Astellas Pharma Inc	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (beta3-Adrenergic Agonist [EPC] class)

· 1 drug in this class
Apgdi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Myrbetriq — Competitive Intelligence Brief. https://druglandscape.com/ci/mirabegron. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab